Approval · Notice of Compliance 1460 · 2000
EVISTA: Notice of Compliance 1460
Issued January 19, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1460
- Date
- January 19, 2000
- Company
- Eli Lilly Canada IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication: treatment of osteoporosis in postmenopausal women
- Therapeutic class
- Selective estrogen receptor modulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| EVISTA | Not yet assigned | — |
Medicinal ingredients
- RALOXIFENE HCL 60 MG per TAB